*Applications will be reviewed on a rolling-basis.A research opportunity is currently available with the Office of the Commissioner (OC) Office of Women’s Health (OWH), U.S. Food and Drug Administration (FDA). The project will be located at the U.S. Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH), Office of Science and Engineering Laboratories (OSEL), Division of Biology, Chemistry, and Materials Science (DBCMS) located in Silver Spring, Maryland.This project will focus on the characterization of surface texture and material properties of breast implants. The research aims to develop an implant surface classification system based on the advanced characterization, identify chemicals and shed particles from surface, and study possible causes to breast implant compilations. Under the guidance of a mentor, the participant will be involved in the following research activities:3D imaging with advanced imaging microscopesSurface property characterizationDeveloping and performing extraction methodsCharacterization of released extractable and particlesInstrument maintenanceDocumenting experimental data and research activitiesGeneral chemistry lab activitiesGeneral microbiology lab activitiesAnticipated Appointment Start Date: Fall 2020This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:Non-employee nature of the ORISE appointment;Prohibition on ORISE Fellows performing inherently governmental functions;Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;The fact that research materials and laboratory notebooks are the property of the FDA;ORISE fellow’s obligation to protect and not to further disclose or use non-public information.If you have questions, send an email to ORISE.FDA.OC.firstname.lastname@example.org.